These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 21958294)

  • 41. T-cell receptor gene therapy targeting melanoma-associated antigen-A4 by silencing of endogenous TCR inhibits tumor growth in mice and human.
    Sun Q; Zhang X; Wang L; Gao X; Xiong Y; Liu L; Wei F; Yang L; Ren X
    Cell Death Dis; 2019 Jun; 10(7):475. PubMed ID: 31209257
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR.
    Cohen CJ; Zheng Z; Bray R; Zhao Y; Sherman LA; Rosenberg SA; Morgan RA
    J Immunol; 2005 Nov; 175(9):5799-808. PubMed ID: 16237072
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bcl-2 overexpression enhances tumor-specific T-cell survival.
    Charo J; Finkelstein SE; Grewal N; Restifo NP; Robbins PF; Rosenberg SA
    Cancer Res; 2005 Mar; 65(5):2001-8. PubMed ID: 15753400
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adoptive T-Cell Transfer to Treat Lymphangioleiomyomatosis.
    Han F; Dellacecca ER; Barse LW; Cosgrove C; Henning SW; Ankney CM; Jaishankar D; Yemelyanov A; Krymskaya VP; Dilling DF; Le Poole IC
    Am J Respir Cell Mol Biol; 2020 Jun; 62(6):793-804. PubMed ID: 32078336
    [TBL] [Abstract][Full Text] [Related]  

  • 45. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
    Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA
    Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapy.
    Cheung NK; Guo HF; Modak S; Cheung IY
    Hybrid Hybridomics; 2003 Aug; 22(4):209-18. PubMed ID: 14511566
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes.
    Marotte L; Simon S; Vignard V; Dupre E; Gantier M; Cruard J; Alberge JB; Hussong M; Deleine C; Heslan JM; Shaffer J; Beauvais T; Gaschet J; Scotet E; Fradin D; Jarry A; Nguyen T; Labarriere N
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 32001504
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term phenotypic, functional and genetic stability of cancer-specific T-cell receptor (TCR) alphabeta genes transduced to CD8+ T cells.
    Hiasa A; Hirayama M; Nishikawa H; Kitano S; Nukaya I; Yu SS; Mineno J; Kato I; Shiku H
    Gene Ther; 2008 May; 15(9):695-9. PubMed ID: 18288212
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genetically modified human CD4(+) T cells can be evaluated in vivo without lethal graft-versus-host disease.
    Ali R; Babad J; Follenzi A; Gebe JA; Brehm MA; Nepom GT; Shultz LD; Greiner DL; DiLorenzo TP
    Immunology; 2016 Aug; 148(4):339-51. PubMed ID: 27124592
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-Tumor Effects after Adoptive Transfer of IL-12 Transposon-Modified Murine Splenocytes in the OT-I-Melanoma Mouse Model.
    Galvan DL; O'Neil RT; Foster AE; Huye L; Bear A; Rooney CM; Wilson MH
    PLoS One; 2015; 10(10):e0140744. PubMed ID: 26473608
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Retrovector encoding a green fluorescent protein-herpes simplex virus thymidine kinase fusion protein serves as a versatile suicide/reporter for cell and gene therapy applications.
    Paquin A; Jaalouk DE; Galipeau J
    Hum Gene Ther; 2001 Jan; 12(1):13-23. PubMed ID: 11177538
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Retroviral vectors for high-level transgene expression in T lymphocytes.
    Engels B; Cam H; Schüler T; Indraccolo S; Gladow M; Baum C; Blankenstein T; Uckert W
    Hum Gene Ther; 2003 Aug; 14(12):1155-68. PubMed ID: 12908967
    [TBL] [Abstract][Full Text] [Related]  

  • 53. TCR gene-engineered T cell: limited T cell activation and combined use of IL-15 and IL-21 ensure minimal differentiation and maximal antigen-specificity.
    Pouw N; Treffers-Westerlaken E; Mondino A; Lamers C; Debets R
    Mol Immunol; 2010 Apr; 47(7-8):1411-20. PubMed ID: 20303179
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor.
    Zhang G; Wang L; Cui H; Wang X; Zhang G; Ma J; Han H; He W; Wang W; Zhao Y; Liu C; Sun M; Gao B
    Sci Rep; 2014 Jan; 4():3571. PubMed ID: 24389689
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Generation of chimeric T-cell receptor transgenes and their efficient transfer in primary mouse T lymphocytes.
    Howland LJ; Haynes NM; Darcy PK
    Methods Mol Biol; 2010; 651():291-306. PubMed ID: 20686973
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rapid re-expression of retrovirally introduced versus endogenous TCRs in engineered T cells after antigen-specific stimulation.
    van Loenen MM; Hagedoorn RS; de Boer R; van Egmond EH; Falkenburg JH; Heemskerk MH
    J Immunother; 2011 Mar; 34(2):165-74. PubMed ID: 21304404
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy.
    Cho HI; Kim UH; Shin AR; Won JN; Lee HJ; Sohn HJ; Kim TG
    Br J Cancer; 2018 Feb; 118(4):534-545. PubMed ID: 29360818
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice.
    Lozupone F; Rivoltini L; Luciani F; Venditti M; Lugini L; Cova A; Squarcina P; Parmiani G; Belardelli F; Fais S
    Eur J Immunol; 2003 Feb; 33(2):556-66. PubMed ID: 12645955
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue.
    Clay TM; Custer MC; McKee MD; Parkhurst M; Robbins PF; Kerstann K; Wunderlich J; Rosenberg SA; Nishimura MI
    J Immunol; 1999 Feb; 162(3):1749-55. PubMed ID: 9973438
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Retroviral transfer of a dominant TCR prevents surface expression of a large proportion of the endogenous TCR repertoire in human T cells.
    Hart DP; Xue SA; Thomas S; Cesco-Gaspere M; Tranter A; Willcox B; Lee SP; Steven N; Morris EC; Stauss HJ
    Gene Ther; 2008 Apr; 15(8):625-31. PubMed ID: 18305579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.